Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer

A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC)

(2017) R. Salgia et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer

(2009) Martin J. Schlumberger et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Sorafenib in Metastatic Thyroid Cancer

(2009) Richard T. Kloos et al.   JOURNAL OF CLINICAL ONCOLOGY

New targets and therapeutic approaches for endocrine malignancies☆

(2009) Martin Fassnacht et al.   PHARMACOLOGY & THERAPEUTICS

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

(2008) Ezra E.W. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Sorafenib in Advanced Thyroid Cancer

(2008) Vandana Gupta-Abramson et al.   JOURNAL OF CLINICAL ONCOLOGY

Thyroid carcinoma: molecular pathways and therapeutic targets

(2008) Yuri E Nikiforov   MODERN PATHOLOGY

Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib

(2008) D. Hong et al.   MOLECULAR CANCER THERAPEUTICS